Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 52Myelodysplastic Syndromes 25Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia 23Lymphoma 22Lymphoma, Non-Hodgkin 21Leukemia, Lymphocytic, Chronic, B-Cell 21Melanoma 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Neoplasms 13Hodgkin Disease 13Neoplasm Metastasis 12Recurrence 11Hematologic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Skin Neoplasms 8Neoplasms, Plasma Cell 8Myeloproliferative Disorders 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Lymphoma, B-Cell 8Kidney Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 7Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Primary Myelofibrosis 5Anemia, Refractory, with Excess of Blasts 5

Interventions

pembrolizumab 3Nivolumab 3Ipilimumab 3Cyclophosphamide 3Radiosurgery 2MART-1 Antigen 2CTLA-4 Antigen 2ulixertinib 1sotrastaurin 1siremadlin 1relatlimab 1pentetreotide 1oblimersen 1incomplete Freund's adjuvant 1fotemustine 1fludarabine phosphate 1fludarabine 1entrectinib 1defactinib 1binimetinib 1benzamide 1aldesleukin 1aflibercept 1Valacyclovir 1Toll-Like Receptor 1 1TYRP1 protein, human 1Sunitinib 1Standard of Care 1RO5126766 1RNA, Messenger 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Uveal Melanoma × fludarabine × Clear all
NCT01814046 2018-10-11

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
24 enrolled 13 charts
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡